These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 19470738)

  • 21. Combination of YM155, a survivin suppressant, with bendamustine and rituximab: a new combination therapy to treat relapsed/refractory diffuse large B-cell lymphoma.
    Kaneko N; Mitsuoka K; Amino N; Yamanaka K; Kita A; Mori M; Miyoshi S; Kuromitsu S
    Clin Cancer Res; 2014 Apr; 20(7):1814-22. PubMed ID: 24486595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma.
    Yu Y; Zhao X; Zhang Y; Kang Y; Wang J; Liu Y
    Oncol Rep; 2015 Jul; 34(1):407-14. PubMed ID: 25955434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics, distribution and excretion of YM155 monobromide, a novel small-molecule survivin suppressant, in male and pregnant or lactating female rats.
    Minematsu T; Sonoda T; Hashimoto T; Iwai M; Oppeneer T; Felder L; Shirai N; Miyashita A; Usui T
    Biopharm Drug Dispos; 2012 Apr; 33(3):160-9. PubMed ID: 22374735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor efficacy and biodistribution of liposomal sepantronium bromide (YM155), a novel small-molecule survivin suppressant.
    Kawano H; Shakushiro K; Nakata M; Kita A; Maeda A; Watanabe S; Sako K; Oku N
    Eur J Pharm Biopharm; 2014 Sep; 88(1):283-9. PubMed ID: 24993306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs.
    Iwasa T; Okamoto I; Takezawa K; Yamanaka K; Nakahara T; Kita A; Koutoku H; Sasamata M; Hatashita E; Yamada Y; Kuwata K; Fukuoka M; Nakagawa K
    Br J Cancer; 2010 Jun; 103(1):36-42. PubMed ID: 20517311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models.
    Nakahara T; Kita A; Yamanaka K; Mori M; Amino N; Takeuchi M; Tominaga F; Kinoyama I; Matsuhisa A; Kudou M; Sasamata M
    Cancer Sci; 2011 Mar; 102(3):614-21. PubMed ID: 21205082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Silencing of survivin using YM155 induces apoptosis and chemosensitization in neuroblastomas cells.
    Liang H; Zhang L; Xu R; Ju XL
    Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2909-15. PubMed ID: 24254560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survivin selective inhibitor YM155 promotes cisplatin‑induced apoptosis in embryonal rhabdomyosarcoma.
    Ueno T; Uehara S; Nakahata K; Okuyama H
    Int J Oncol; 2016 May; 48(5):1847-54. PubMed ID: 26983495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Involvement of human organic cation transporter 1 in the hepatic uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel, small molecule survivin suppressant.
    Iwai M; Minematsu T; Narikawa S; Usui T; Kamimura H
    Drug Metab Dispos; 2009 Sep; 37(9):1856-63. PubMed ID: 19520775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant.
    Minematsu T; Iwai M; Umehara K; Usui T; Kamimura H
    Drug Metab Dispos; 2010 Jan; 38(1):1-4. PubMed ID: 19833842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting of Survivin Pathways by YM155 Inhibits Cell Death and Invasion in Oral Squamous Cell Carcinoma Cells.
    Zhang W; Liu Y; Li YF; Yue Y; Yang X; Peng L
    Cell Physiol Biochem; 2016; 38(6):2426-37. PubMed ID: 27287458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells.
    Tao YF; Lu J; Du XJ; Sun LC; Zhao X; Peng L; Cao L; Xiao PF; Pang L; Wu D; Wang N; Feng X; Li YH; Ni J; Wang J; Pan J
    BMC Cancer; 2012 Dec; 12():619. PubMed ID: 23267699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of autophagy-dependent apoptosis by the survivin suppressant YM155 in prostate cancer cells.
    Wang Q; Chen Z; Diao X; Huang S
    Cancer Lett; 2011 Mar; 302(1):29-36. PubMed ID: 21220185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survivin and YM155: how faithful is the liaison?
    Rauch A; Hennig D; Schäfer C; Wirth M; Marx C; Heinzel T; Schneider G; Krämer OH
    Biochim Biophys Acta; 2014 Apr; 1845(2):202-20. PubMed ID: 24440709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies.
    Forouzesh B; Hidalgo M; Chu Q; Mita A; Mita M; Schwartz G; Jimeno J; Gómez J; Alfaro V; Lebedinsky C; Zintl P; Rowinsky EK
    Clin Cancer Res; 2009 May; 15(10):3591-9. PubMed ID: 19417019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic antitumor activities of sepantronium bromide (YM155), a survivin suppressant, in combination with microtubule-targeting agents in triple-negative breast cancer cells.
    Kaneko N; Yamanaka K; Kita A; Tabata K; Akabane T; Mori M
    Biol Pharm Bull; 2013; 36(12):1921-7. PubMed ID: 24432379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radiosynthesis, biodistribution and imaging of [11C]YM155, a novel survivin suppressant, in a human prostate tumor-xenograft mouse model.
    Murakami Y; Matsuya T; Kita A; Yamanaka K; Noda A; Mitsuoka K; Nakahara T; Miyoshi S; Nishimura S
    Nucl Med Biol; 2013 Feb; 40(2):221-6. PubMed ID: 23141550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting response to sepantronium bromide (YM155), a survivin suppressant, by PET imaging with [
    Mitsuoka K; Kita A; Murakami Y; Shirasuna K; Noda A; Yamanaka K; Kaneko N; Miyoshi S
    Nucl Med Biol; 2018; 64-65():41-46. PubMed ID: 30041149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma.
    Kita A; Nakahara T; Yamanaka K; Nakano K; Nakata M; Mori M; Kaneko N; Koutoku H; Izumisawa N; Sasamata M
    Leuk Res; 2011 Jun; 35(6):787-92. PubMed ID: 21237508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.